# OnCo record lori-wirth (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/lori-wirth/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "lori-wirth" ;
  schema:name "Lori J. Wirth"@en ;
  schema:description "Led LIBRETTO-001 in thyroid cancer, which made selpercatinib the first RET-selective drug approved for RET-driven tumours."@en ;
  schema:url <https://onco.cc/people/lori-wirth/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=Wirth%20LJ%5BAuthor%5D%20thyroid%20selpercatinib> ;
  onco:tag "thyroid", "ret", "targeted-therapy" ;
  schema:jobTitle "Medical Director, Center for Head and Neck Cancers, Massachusetts General Hospital Cancer Center" ;
  onco:cancers <https://onco.cc/cancers/thyroid/>, <https://onco.cc/cancers/head-and-neck/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/ret/> ;
  onco:drugs <https://onco.cc/drugs/selpercatinib/> ;
  onco:institutions <https://onco.cc/institutions/mgh/> ;
  onco:trials <https://onco.cc/trials/libretto-531/> ;
  schema:affiliation <https://onco.cc/institutions/mgh/> .